The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
本公开涉及改良的Relaxin
多肽,例如改良的人类Relaxin 2
多肽,包括与药代增强剂相连的非自然编码
氨基酸,并且这些
多肽的治疗用途,例如用于治疗心血管疾病(如心力衰竭)和/或与纤维化相关的疾病。